Literature DB >> 27355549

Weekly vs. Every-3-Week Paclitaxel for Ovarian Cancer.

John K Chan, Mark F Brady, Bradley J Monk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27355549     DOI： 10.1056/NEJMc1603849

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer.

Authors:  Fangfei Li; Jun Lu; Jin Liu; Chao Liang; Maolin Wang; Luyao Wang; Defang Li; Houzong Yao; Qiulong Zhang; Jia Wen; Zong-Kang Zhang; Jie Li; Quanxia Lv; Xiaojuan He; Baosheng Guo; Daogang Guan; Yuanyuan Yu; Lei Dang; Xiaohao Wu; Yongshu Li; Guofen Chen; Feng Jiang; Shiguo Sun; Bao-Ting Zhang; Aiping Lu; Ge Zhang
Journal:  Nat Commun       Date:  2017-11-09       Impact factor: 14.919

Review 2.  Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.

Authors:  Dong Hoon Suh; Miseon Kim; Kidong Kim; Hak Jae Kim; Kyung Hun Lee; Jae Weon Kim
Journal:  J Gynecol Oncol       Date:  2017-03-24       Impact factor: 4.401

3.  Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer.

Authors:  Sol-Bi Shin; Sang-Uk Woo; Hyungshin Yim
Journal:  Ther Adv Med Oncol       Date:  2019-05-08       Impact factor: 8.168

4.  Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.

Authors:  Carol Aghajanian; Elizabeth M Swisher; Aikou Okamoto; Karina Dahl Steffensen; Michael A Bookman; Gini F Fleming; Michael Friedlander; Kathleen N Moore; Krishnansu S Tewari; David M O'Malley; John K Chan; Christine Ratajczak; Hideyuki Hashiba; Meijing Wu; Minh H Dinh; Robert L Coleman
Journal:  Gynecol Oncol       Date:  2021-12-18       Impact factor: 5.304

5.  Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance.

Authors:  Sol-Bi Shin; Chang-Hyeon Kim; Hay-Ran Jang; Hyungshin Yim
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.